Sequential Hosts London Summit on AI-Driven Ingredient Discovery
On December 3, 2026, London’s King's Cross will host a gathering of R&D leaders tasked with navigating the intersection of artificial intelligence and clinical validation. Held at The Mills Fabrica, the Sequential-led forum marks a shift in how the beauty and biotechnology sectors verify the efficacy of next-generation ingredients.
The one-day conference addresses a fundamental tension in the personal care market: as AI and multi-omics accelerate the pace of ingredient discovery, brands face mounting pressure to provide more rigorous scientific proof. Dr. Oliver Worsley, CEO and co-founder of Sequential, frames the event as a necessary response to a market demanding higher standards of evidence for bioengineered and longevity-focused products.
Keynote speaker Lieve Declercq of Proya Companies will anchor a program featuring insights from industry veterans, including Dr. Martin Pagac of dsm-firmenich, Christina Patane of Medik8, and John Milligan of The Honey Pot Company. The agenda moves beyond theoretical discussion, focusing on peer-to-peer knowledge sharing regarding real-world innovation cases and the application of multi-omics studies. With experts like Dr. Amir Jassim and S-Biomedic’s Veronika Oudova also contributing, the event aims to bridge the gap between discovery and consumer-facing validation.
Comments (0)
No comments yet. Be the first!